“The importance of diverse representation cannot be underscored enough and is critical to ensure that safe and effective products are available to the [United States] patient population,” wrote the study authors, who were led by Nicole Gormley, MD.
Given the current study findings, investigators suggested intratherapy personalization of chemoradiotherapy may possibly facilitate marked de-escalation of radiotherapy in patients with HPV-related oropharyngeal cancers.
In a phase 2 study, adavosertib plus gemcitabine showed signs of activity in platinum-resistant or platinum-refractory advanced high-grade serous ovarian cancer, including rare histological subtypes of ovarian cancer.
“Our results support further study of serial molecular imaging along with combined [histone deacetylase inhibitors; HDACi] and [aromatase inhibitor; AI] therapy (such as ECOG-ACRIN study E2112), to further delineate the role of HDACi and potential biomarkers in AI-refractory ER+ advanced breast cancer,” wrote the study authors.
“The [phase 1b/2] data [are] promising and support the current phase 3, multicenter trial, which we hope will lead to FDA approval and a new much-needed treatment option for this patient population,” said David Sallman, MD.
“Emerging evidence supports a possible role for overall dietary patterns that, in totality, emphasize habitually consuming fruits, vegetables, grains, and low-fat dairy and reducing red meat and alcohol intake,” wrote the study authors.
Given these study findings, investigators suggested that future efforts should address racial/ethnic, educational, financial, and geographic barriers to receiving digital breast tomosynthesis screening at the facility level.